Inclisiran receives reimbursement and enters clinical practice
Authors:
Kristýna Čillíková
Authors place of work:
Česká společnost pro aterosklerózu
Published in the journal:
AtheroRev 2023; 8(2): 117-120
Category:
Announcements
Zdroje
1. Ray KK, Kallend D, Leiter LA et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J 2022; 43(48): 5047–5057. <https://doi.org/10.1093/eurheartj/ehac615>.
2. Wright RS, Ray KK et al. Impact of Inclisiran on LDL-C Over 18 months in Patients With ASCVD or Risk-Equivalent - ORION-11. American College of Cardiology. Dostupné z WWW: <https://www.acc.org/latest-in-cardiology/ clinical-trials/2019/09/01/12/22/orion-11>.
Štítky
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsČlánok vyšiel v časopise
Athero Review
2023 Číslo 2
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Memantine in Dementia Therapy – Current Findings and Possible Future Applications
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Bempedoic acid in the context of current hypolipidemic treatment options and the results of the CLEAR OUTCOMES trial
- Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
- The importance of nonstatin therapies for LDL-cholesterol lowering in the management of very high and high atherosclerotic cardiovascular risk
- Hyperlipidemic crisis as a risk factor for acute pancreatitis